Skip to main content
2026 SECO Annual Congress Main banner
Final Program


Paul M. Karpecki, OD

Lexington, KY, United States

Paul M. Karpecki, OD, FAAO, received his Doctor of Optometry degree from Indiana University and completed a fellowship in medical cornea in Kansas City in affiliation with the Pennsylvania College of Optometry, now Salus University. He currently serves as Director, Cornea and External Disease at Kentucky Eye Institute in Lexington KY. Dr. Karpecki served on the DEWS II Diagnostic subcommittee, the DEWS III Treatment subcommittee and was the invited co-chair for the last three TFOS Symposia. He runs the largest advanced dry eye clinic in the United States. As an example he has over 600 Sjogrens’ Disease KCS patients under his care, which is a small percentage of the dry eye population he serves. He completed a full year preceptorship in advanced retinal disease at Retina Associates of Kentucky, a top 20 retina practice and remained on staff for an additional 2 years to advance his knowledge in the field of uveitis and retinal disease. A noted educator and author, Dr. Karpecki has provided over 2000 lectures at various meetings covering 4 continents. He has also authored over 1500 papers in journals, book chapters, clinical eblasts and newsletters. He has published over 85 peer-reviewed manuscripts in major journals. He currently serves as the Chief Clinical Editor for Review of Optometry, the most read journal in the profession. He Chairs the New Technology and Treatment Conferences as well as the Ocular Surface Symposia for Medscape. He is also a board member and treasurer for the charitable organization Optometry Giving Sight.

Presentation(s):

  • 62 - Special Session - The Tried, The True, & The New in Ocular Surface Disease

    Friday, February 27, 2026
    9:00 AM - 11:00 AM EDT

    Disclosure(s): AbbVie/Allergan: Consulting Fees (); AI Optics: Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (); Alcon: Consulting Fees (), Speaker's Bureau (honoraria or other compensation) (); Aramis: Advisory Committee/Board Member (), Consulting Fees (); Atlas Ocular: Consulting Fees (); Azura: Consulting Fees (); Barti: Consulting Fees (); Bausch + Lomb: Advisory Committee/Board Member (), Consulting Fees (), Speaker's Bureau (honoraria or other compensation) (); BioTissue: Advisory Committee/Board Member (), Consulting Fees (); Blephex: Consulting Fees (), Speaker's Bureau (honoraria or other compensation) (); Bruder Healthcare/Hilco: Advisory Committee/Board Member (), Consulting Fees (); Bruno Vision Care: Consulting Fees (); Cambium: Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (); Danelli Ocular Creations: Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (); Dompe: Consulting Fees (), Speaker's Bureau (honoraria or other compensation) (); Essilor: Consulting Fees (); Eyedaptec: Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (); Eyedetec: Consulting Fees (); Harrow: Consulting Fees (), Researcher (grant funding or other support) (), Speaker's Bureau (honoraria or other compensation) (); Healthe: Advisory Committee/Board Member (), Consulting Fees (), Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (); Hui.AI: Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (); iCare: Consulting Fees (); iOR Holdings: Consulting Fees (), Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (); Iveena: Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (); LeGrande: Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (); LenTechs: Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (); Lexitas: Advisory Committee/Board Member (), Consulting Fees (); Lubris: Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (); Mallinckrodt: Speaker's Bureau (honoraria or other compensation) (); Mati Therapeutics: Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (); Neurolens: Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (); Nordic Pharma: Consulting Fees (); Oasis Medical: Consulting Fees (); Oculus: Consulting Fees (); OcuSoft: Consulting Fees (); Omega Ophthalmics: Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (); Ophthalmic Resources: Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (); Orasis: Advisory Committee/Board Member (), Consulting Fees (), Speaker's Bureau (honoraria or other compensation) (); Percept: Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (); RegenerEyes: Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (); Rendia: Consulting Fees (); RxSight: Consulting Fees (); Science Based Health: Consulting Fees (); Scope: Consulting Fees (); Sentiss: Consulting Fees (); Sight Sciences: Consulting Fees (); Signal 12: Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (); Silk Tears: Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (); Stuart Pharmaceuticals: Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (); Surface Pharma: Advisory Committee/Board Member (), Consulting Fees (), Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (); Sydnexis: Consulting Fees (), Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (); Tarsus Pharma: Advisory Committee/Board Member (), Consulting Fees (), Speaker's Bureau (honoraria or other compensation) (); TecLens: Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (); Thea Laboratories: Consulting Fees (); Topcon: Consulting Fees (); Vision Path: Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (); Vital Tears: Consulting Fees ()